Wockhardt launches an authorized generic of Parkinson's drug Stalevo

24 Apr 2012 Evaluate

Pharmaceutical and biotechnology major, Wockhardt has launched an authorized generic version of four strengths (50mg, 75mg, 125mg and 200mg) of the triple-drug combination product containing Levodopa, Carbidopa and Entacapone, which are used in treatment of Parkinson's disease. The tablet is the generic name for the brand Stalevo owned by Orion Corporation and marketed in the United States by Novartis and is entitled to 180-days of exclusivity.

Wockhardt is one of the select companies with end to end integrated capabilities for its products, starting with manufacture of the oral and sterile API’s, the dose forms and marketing through the wholly owned subsidiary in the US.

Wockhardt, is engaged the pharmaceutical and biotechnology segments. The company’s 14 manufacturing plants are located in India, UK, Ireland, US, and are compliant to international regulatory standards including US FDA and UK MHRA. These manufacturing plants are multi-technology and can manufacture all the dosage forms including sterile products as well as products with lyophilised dosage forms.

Wockhardt Share Price

1230.95 58.60 (5.00%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.